Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression
about
G9A performs important roles in the progression of breast cancer through upregulating its targets.The proteome signature of the inflammatory breast cancer plasma membrane identifies novel molecular markers of diseaseSyndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathwaysGanoderma spp.: A Promising Adjuvant Treatment for Breast Cancer.Developing an Agent-Based Drug Model to Investigate the Synergistic Effects of Drug Combinations.
P2860
Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Ganoderma lucidum Combined wit ...... tory Breast Cancer Progression
@ast
Ganoderma lucidum Combined wit ...... tory Breast Cancer Progression
@en
type
label
Ganoderma lucidum Combined wit ...... tory Breast Cancer Progression
@ast
Ganoderma lucidum Combined wit ...... tory Breast Cancer Progression
@en
prefLabel
Ganoderma lucidum Combined wit ...... tory Breast Cancer Progression
@ast
Ganoderma lucidum Combined wit ...... tory Breast Cancer Progression
@en
P2093
P2860
P356
P1433
P1476
Ganoderma lucidum Combined wit ...... tory Breast Cancer Progression
@en
P2093
Daniel J Leal-Alviarez
Gerónimo Maldonado-Martinez
Luis A Cubano
Mercedes Lacourt-Ventura
Tiffany J Rios-Fuller
Yismeilin R Feliz-Mosquea
P2860
P304
P356
10.7150/JCA.13599
P577
2016-02-05T00:00:00Z